

Atopic Eczema in Adulthood: Unraveling the Link to Depression and Anxiety: A Comprehensive Cohort Study

Firdous Jahan¹, Md Shahnawaz Zafar²

¹Assistant Professor, Department of Skin & VD, Sheikh Bhikhari Medical College, Hazaribagh, Jharkhand, India

²Assistant Professor, Department of Psychiatry, Sheikh Bhikhari Medical College, Hazaribagh, Jharkhand, India

Received: 25-10-2023 / Revised: 23-11-2023 / Accepted: 26-12-2023

Corresponding Author: Firdous Jahan

Conflict of interest: Nil

Abstract:

This comprehensive cohort study investigates the association between atopic eczema in adulthood and the onset of depression and anxiety. By analysing 500 adults diagnosed with atopic eczema and a matched control group without the condition, the study explores the prevalence and severity of depressive and anxious symptoms in these populations. The research highlights a significant association between atopic eczema and increased risks of depression and anxiety, emphasizing a dose-response relationship where higher eczema severity correlates with greater mental health risks. The findings suggest that systemic immunosuppressants may offer some benefits in improving mental health outcomes alongside conventional dermatological treatments. These results advocate for integrated care approaches that address both dermatological and psychological needs, enhancing overall patient well-being.

Keywords: Atopic Eczema, Depression, Anxiety, Integrated Care.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Atopic eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition characterized by itchy, red, swollen, and cracked skin. While it is most commonly associated with childhood, atopic eczema can persist into or even start during adulthood, affecting the quality of life of millions worldwide. Recent studies have increasingly recognized the psychological impact of this condition, suggesting a significant association between atopic eczema in adults and the development of mental health disorders such as depression and anxiety.

This comprehensive cohort study aims to explore and elucidate the potential link between atopic eczema in adulthood and the onset of depression and anxiety. By examining a diverse group of adults diagnosed with atopic eczema, this study seeks to assess the prevalence and severity of depressive and anxious symptoms within this population compared to controls without eczema. Additionally, the research will investigate the mechanisms that might contribute to these psychological outcomes, including the role of chronic stress, inflammation, and disruptions in daily functioning due to the physical symptoms of eczema.

Understanding the connections between atopic eczema and mental health disorders is crucial for developing targeted interventions that can improve

both dermatological and psychological outcomes for this vulnerable population. Through rigorous data collection and analysis, this study aims to provide a deeper understanding of these complex interrelations and pave the way for holistic treatment approaches that address both the skin and the psyche.

This study aims to systematically investigate the association between atopic eczema in adulthood and the incidence of depression and anxiety by determining the prevalence and severity of these mental health disorders among adults with atopic eczema compared to a control group without the condition. This research will also explore the potential physiological and psychological mechanisms, such as chronic inflammation, stress responses, and lifestyle limitations, through which atopic eczema may influence mental health. Additionally, it will assess the impact of demographic and lifestyle factors, including age, gender, socioeconomic status, and lifestyle habits, on the mental health outcomes of individuals with atopic eczema. The ultimate goal is to enhance our understanding of the complex interactions between chronic physical conditions and mental health, leading to improved therapeutic strategies and better quality of life for those affected.

Material and Methodology

1. Study Design: Longitudinal Cohort Study: Follows a group of individuals with atopic eczema and a control group over an extended period.

2. Participant Selection:

- Inclusion Criteria:

- Adults aged 18-65 years.

- Diagnosed with atopic eczema by a dermatologist using standardized criteria.

- Exclusion Criteria:

- Individuals with other dermatological conditions that may confound the results.

- History of severe mental illness before the onset of atopic eczema.

3. Control Group Selection:

- Matched for age, gender, and socioeconomic status.

- No history of atopic eczema or other chronic skin conditions.

4. Recruitment and Informed Consent:

- Participants were recruited from dermatology clinics, community health centers, and online platforms.

- Informed consent was obtained from all participants before enrollment.

5. Baseline Assessment:

- Detailed medical history, including eczema severity, duration, and treatment history.

- Baseline assessment of depression and anxiety using standardized tools such as PHQ-9 and GAD-7.

7. Socio-demographic data collection.

6. Follow-up Assessments:

- Regular follow-up intervals (e.g., every 6 months) for a minimum of 2 years.

- Assessment of eczema severity, treatment changes, and adherence.

- Periodic assessment of depression and anxiety using standardized tools.

- Any significant life events or changes in medication record.

7. Data Collection:

- Quantitative data was collected through structured interviews and validated questionnaires.

- Qualitative data was collected through open-ended questions to understand participants' experiences and perceptions.

- Data on confounding variables (e.g., comorbidities, lifestyle factors) was also collected.

8. Statistical Analysis:

- Descriptive statistics are used to summarize participant characteristics and study variables.

- Longitudinal data analysis techniques (e.g., mixed-effects models) to examine the relationship between atopic eczema, depression, and anxiety over time.

- Adjustments made for potential confounders using regression models.

- Subgroup analyses based on eczema severity, treatment modalities, and socio-demographic factors.

9. Ethical Considerations:

- Study conducted by ethical guidelines and regulations.

- Data anonymized to ensure participant confidentiality.

- Provision of psychological support or referral for participants experiencing distress.

10. Dissemination of Findings:

- Publication of results in peer-reviewed journals and presentation at relevant conferences.

- Provision of lay summaries for participants and community stakeholders.

- Integration of findings into clinical practice guidelines for the management of atopic eczema and mental health comorbidities.

11. Limitations:

- Potential for selection bias due to recruitment from specialized clinics.

- Difficulty in establishing causality due to the observational nature of the study.

- Loss to follow-up and attrition over the study period.

Results

Participant Characteristics

Total Participants: 500 individuals with atopic eczema and 500 controls were enrolled in the study.

Demographic Characteristics:

- Mean age \pm SD: 42.5 \pm 10.3 years in the atopic eczema group and 43.2 \pm 10.1 years in the control group.

- Gender distribution: Similar between groups, with 55% female participants in both groups.

- Socioeconomic status: Comparable between groups based on education level and household income.

Baseline Characteristics

Eczema Severity:

- Mild: 35% of participants.
- Moderate: 50% of participants.
- Severe: 15% of participants.
- ****Depression and Anxiety Scores**:**
- Atopic Eczema Group: Mean PHQ-9 score ± SD: 9.8 ± 4.2; Mean GAD-7 score ± SD: 8.6 ± 3.9.
- Control Group: Mean PHQ-9 score ± SD: 5.2 ± 2.9; Mean GAD-7 score ± SD: 4.8 ± 2.5.

Treatment Modalities:

- Topical corticosteroids: Most commonly used (80% of participants), followed by emollients (60%) and antihistamines (40%).
- 25% of participants in the atopic eczema group reported using systemic immunosuppressants.

Longitudinal Analysis

Association between Atopic Eczema and Depression/Anxiety:

- Adjusted longitudinal analysis revealed a significant association between atopic eczema and increased risk of depression (Adjusted Odds Ratio [AOR]: 2.4, 95% CI: 1.8-3.2) and anxiety (AOR: 2.1, 95% CI: 1.6-2.7) compared to controls.
- Subgroup analysis showed a dose-response relationship between eczema severity and the risk of depression and anxiety, with higher severity associated with greater risk.

Treatment Effects

Impact of Treatment on Mental Health:

- Participants receiving systemic immunosuppressants for eczema showed a modest reduction in depression and anxiety scores over time compared to those using topical treatments alone.
- Adherence to treatment regimens was positively correlated with improved mental health outcomes among participants with atopic eczema.

Qualitative Findings

Participant Perspectives:

- Qualitative analysis of open-ended responses highlighted themes of frustration, embarrassment, and reduced quality of life associated with atopic eczema.
- Many participants expressed challenges in managing both their skin condition and mental health, emphasizing the need for integrated care approaches.

Limitations

Loss to Follow-up: Approximately 20% of participants were lost to follow-up over the study period, potentially introducing selection bias.

Generalizability: Findings may not be generalizable to populations outside the study setting or to individuals with severe mental illness.

Causality: Despite longitudinal design, causality cannot be inferred due to the observational nature of the study.

Table 1: This table provides a concise summary of the key findings, including participant characteristics, baseline characteristics, longitudinal analysis results, treatment effects, qualitative findings, and study limitations.

Results	
Participant Characteristics	
Total Participants	500 individuals with atopic eczema and 500 controls were enrolled in the study.
Demographic Characteristics:	
Mean age ± SD	42.5 ± 10.3 years in the atopic eczema group 43.2 ± 10.1 years in the control group.
Gender distribution	Similar between groups, with 55% female participants in both groups.
Socioeconomic status	Comparable between groups based on education level and household income.
Baseline Characteristics	
Eczema Severity	Mild: 35% of participants. Moderate: 50% of participants. Severe: 15% of participants.
Depression and Anxiety Scores	Atopic Eczema Group: Mean PHQ-9 score ± SD: 9.8 ± 4.2; Mean GAD-7 score ± SD: 8.6 ± 3.9. Control Group: Mean PHQ-9 score ± SD: 5.2 ± 2.9; Mean GAD-7 score ± SD: 4.8 ± 2.5.
Treatment Modalities	Topical corticosteroids: 80% of participants; Emollients: 60% of participants; Antihistamines: 40% of participants. Systemic immunosuppressants: 25% of participants in the atopic eczema group.
Longitudinal Analysis	

Association between Atopic Eczema and Depression/Anxiety	Adjusted Odds Ratio (AOR): 2.4 (95% CI: 1.8-3.2) for depression; AOR: 2.1 (95% CI: 1.6-2.7) for anxiety compared to controls. Sub-group analysis showed a dose-response relationship between eczema severity and the risk of depression and anxiety, with higher severity associated with greater risk.
Treatment Effects	
Impact of Treatment on Mental Health	Participants receiving systemic immunosuppressants for eczema showed a modest reduction in depression and anxiety scores over time compared to those using topical treatments alone. Adherence to treatment regimens was positively correlated with improved mental health outcomes among participants with atopic eczema.
Qualitative Findings	
Participant Perspectives	Qualitative analysis of open-ended responses highlighted themes of frustration, embarrassment, and reduced quality of life associated with atopic eczema. Many participants expressed challenges in managing both their skin condition and mental health, emphasizing the need for integrated care approaches.
Limitations	
Loss to Follow-up	Approximately 20% of participants were lost to follow-up over the study period, potentially introducing selection bias.
Generalizability	Findings may not be generalizable to populations outside the study setting or to individuals with severe mental illness.
Causality	Despite longitudinal design, causality cannot be inferred due to the observational nature of the study.

Discussion

1. Association between Atopic Eczema and Mental Health:

- Consistent with previous literature, we observed a significant association between atopic eczema and increased risk of depression and anxiety in adulthood. This association persisted even after adjusting for potential confounders, highlighting the robustness of the findings.

2. Severity Gradient and Mental Health Outcomes:

- Importantly, our study demonstrated a dose-response relationship between eczema severity and the risk of depression and anxiety. Individuals with more severe eczema experienced a disproportionately higher burden of mental health issues, underscoring the clinical significance of disease severity in the context of mental health outcomes.

3. Treatment Effects:

- Our findings suggest that while conventional treatments for atopic eczema, such as topical corticosteroids and emollients, play a crucial role in managing the skin condition, their impact on mental health outcomes may be limited. However, participants receiving systemic immunosuppressants showed modest improvements in depression and anxiety scores over time, indicating a potential avenue for integrated treatment approaches targeting both skin and mental health.

Mechanisms and Implications1. Biopsychosocial Model:

- The observed association between atopic eczema and depression/anxiety lends support to the biopsychosocial model, which posits complex interactions between biological, psychological, and social factors in shaping health outcomes. Chronic inflammation, altered stress response systems, and psychosocial stressors associated with eczema may contribute to the development or exacerbation of mental health disorders.

2. Clinical Implications:

- Our findings underscore the importance of holistic, multidisciplinary care approaches for individuals with atopic eczema, addressing not only the physical symptoms but also the psychological and social dimensions of the condition. Dermatologists, in collaboration with mental health professionals, should prioritize routine screening for depression and anxiety among eczema patients and offer timely interventions to mitigate mental health comorbidities.

Strengths and Limitations

1. Strengths:

- The longitudinal design of our study allowed for the examination of temporal relationships between eczema and mental health outcomes, enhancing the robustness of the findings.

- Integration of both quantitative and qualitative data provided a comprehensive understanding of the

lived experiences of individuals with atopic eczema and their mental health challenges.

2. Limitations:

- Despite efforts to minimize bias, loss to follow-up and attrition rates may have influenced the generalizability of our findings.
- The observational nature of the study precludes causal inference, and unmeasured confounders may have influenced the observed associations.

Future Directions

1. Mechanistic Studies:

- Future research should aim to elucidate the underlying biological mechanisms linking atopic eczema to depression and anxiety, including the role of immune dysregulation, neuroinflammation, and psychosocial stressors.

2. Interventional Studies:

- Randomized controlled trials are warranted to evaluate the efficacy of integrated treatment approaches targeting both eczema and mental health outcomes, with a focus on optimizing patient-centered care and improving quality of life.

Our study contributes to a growing body of evidence highlighting the intricate interplay between atopic eczema and mental health in adulthood. By recognizing and addressing the psychosocial dimensions of eczema care, clinicians can enhance patient well-being and improve treatment outcomes in this vulnerable population.

Conclusion

In this comprehensive cohort study exploring the relationship between atopic eczema in adulthood and the risk of depression and anxiety, we found a significant association between atopic eczema and heightened mental health risks, with a dose-response relationship observed between eczema severity and the likelihood of depression and anxiety. While conventional treatments play a pivotal role, our findings suggest potential benefits from systemic immunosuppressants in improving mental health outcomes, alongside the importance of treatment adherence. Qualitative insights underscored the lived experiences of individuals with eczema, highlighting the need for holistic, patient-centered care approaches. These findings emphasize the bidirectional relationship between atopic eczema and mental health, advocating for integrated care models to optimize patient well-being.

References

1. Morales E, Alcantara-Lopez MV, Cabezas-Herrera J, de Diego T, Hernandez-Caselles T, Jimenez-Guerrero P, Larque E, Lopez-Soler C, Martinez-Gracia C, Martinez-Torres A, Martin-

- Orozco E. The Nutrition in Early Life and Asthma (NELA) birth cohort study: Rationale, design, and methods. *Paediatric and Perinatal Epidemiology*. 2022 Mar;36(2):310-24.
2. Yang Y, Gong T, Camargo Jr CA, Valdimarsdóttir UA, Bertone-Johnson E, Lu D. Childhood asthma, allergies and risk of premenstrual disorders in young adulthood. *Nature Mental Health*. 2023 Jun;1(6):410-9.
3. Calam R, Gregg L, Simpson A, Simpson B, Woodcock A, Custovic A. Behavior problems antecede the development of wheeze in childhood: a birth cohort study. *American journal of respiratory and critical care medicine*. 2005 Feb 15;171(4):323-7.
4. Afshari M, Kolackova M, Rosecka M, Čelakovská J, Krejsek J. Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches. *Frontiers in Immunology*. 2024 Mar 4;15: 1361005.
5. Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, Kieboom BC, Klaver CC, de Kneegt RJ, Luik AI, Nijsten TE. Objectives, design and main findings until 2020 from the Rotterdam Study. *European journal of epidemiology*. 2020 May; 35:483-51 7.
6. Prados-Torres A, Poblador-Plou B, Gimeno-Miguel A, Calderón-Larrañaga A, Poncel-Falcó A, Gimeno-Feliú LA, González-Rubio F, Laguna-Berna C, Marta-Moreno J, Clerencia-Sierra M, Aza-Pascual-Salcedo M. Cohort profile: the epidemiology of chronic diseases and multimorbidity. The EpiChron cohort study. *International journal of epidemiology*. 2018 Apr 1;47(2):382-4f.
7. Ioakeim-Skoufa I, Poblador-Plou B, Carmona-Pérez J, Díez-Manglano J, Navickas R, Gimeno-Feliú LA, González-Rubio F, Jureviciene E, Dambrauskas L, Prados-Torres A, Gimeno-Miguel A. Multimorbidity patterns in the general population: results from the EpiChron cohort study. *International journal of environmental research and public health*. 2020 Jun;17(12):4242.
8. Za'im Ramli R, Hadi H, Sarker ZI, Alwid AA. Psychosocial and Socioeconomic Impacts of Atopic Dermatitis: A Comprehensive Review. *Journal of Pharmacy*. 2023 Jul 31;3(2):103-15.
9. Yew YW. Relationship of atopic dermatitis with obesity and its related inflammatory metabolic disturbances in an adult general population cohort.
10. Amadou C, Heude B, de Lauzon-Guillain B, Lioret S, Descarpentrie A, Ribet C, Zins M, Charles MA. Early origins of metabolic and overall health in young adults: an outcome-wide analysis in a general cohort population. *Diabetes & Metabolism*. 2023 Mar 1;49(2):10 1414.
11. Ikram MA, Kieboom BC, Brouwer WP, Brusselle G, Chaker L, Ghanbari M, Goedegebure

- A, Ikram MK, Kavousi M, de Knecht RJ, Luik AI. The Rotterdam Study. Design update and major findings between 2020 and 2024. *European Journal of Epidemiology*. 2024 Feb 7;1-24.
12. Traidl S, Werfel T, Traidl-Hoffmann C. Atopic eczema: pathophysiological findings as the beginning of a new era of therapeutic options. In *Allergic Diseases—From Basic Mechanisms to Comprehensive Management and Prevention*. Cham: Springer International Publishing. 2021 Jul 9;101-115.
13. Eldeiry D, Zandy M, Tayer-Shifman OE, Kwan A, Marzouk S, Su J, Bingham K, Touma Z. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus. *Rheumatology*. 2020 Nov;59(11):3211-20.